MD Learning Channel - Transplant
Managing Acute Kidney Injury in COVID-19 Patients
Dr. Ashita Tolwani discusses the management of acute kidney injury in COVID-19 patients.Learning Objectives: Upon completion of this CME activity, participants should be able to:
- Understand how to manage acute kidney injury in patients with COVID-19
- Identify best practices relating to acute kidney injury in patients with COVID-19
- Understand continuous renal replacement therapy (CRRT)
- Consulting Fee - Baxter Healthcare
- Patents (planned, pending or issued) - Royalties from Baxter for patent
- Royalties - Royalties from Baxter for patent
- Payment for Lectures, including Service on Speakers' Bureaus - Baxter Healthcare
Dr. Tolwani does not intend to discuss the off-label use of a product. No other speakers, planners or content reviewers have any relevant financial relationships to disclose. There is no commercial support for this activity.
Accreditation Statement: The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this online enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.Take Test Now >>
Overview of Kidney Transplantation Program
The UAB transplant program's primary goal is help patients get transplanted as quickly as possible. Through our expanded programs, patients are offered several transplant options such as living-donor kidney transplant, paired-kidney exchange, and incompatible kidney and desensitization.
Paired Exchange Program & Desensitization
Not every program in the country offers incompatitble transplantation leaving a large disenfranchised patient population. Jayme Locke, MD, explains that these highly-sensitized patients can benefit from UAB's incompatible kidney transplant program.
Solutions to Donor-Recipient Incompatibility
About 35% of patients that come forward with living donors will be found to be blood-group incompatible, and another 11% are found to be tissue-incompatible with their potential living donor. Transplant surgeon, Jayme Locke MD, discusses solutions such as desensitation for this large patient population.
The Incompatible Program: How it works
Blood-group compatibility and histocompatibility must be determined prior to transplant. With a positive cross-match precluding transplantation, transplant nephrologist, Vineeta Kumar MD, explains how these matches are determined and how technology can be used to rectify this incompatible transplant.